{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:34:02Z","timestamp":1789785242823,"version":"4.0.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s11910-017-0778-2","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T04:39:17Z","timestamp":1500871157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["New Therapeutic Strategies for Lewy Body Dementias"],"prefix":"10.1007","volume":"17","author":[{"given":"Latha","family":"Velayudhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Ffytche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"issue":"10004","key":"778_CR1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","volume":"386","author":"Z Walker","year":"2015","unstructured":"Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683\u201397.","journal-title":"Lancet"},{"issue":"5","key":"778_CR2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S1474-4422(17)30074-1","volume":"16","author":"C Mueller","year":"2017","unstructured":"Mueller C, Ballard C, Corbett A, Aarsland D. The prognosis of dementia with Lewy bodies. Lancet Neurol. 2017;16(5):390\u20138.","journal-title":"Lancet Neurol"},{"key":"778_CR3","doi-asserted-by":"crossref","unstructured":"\u2022 Matsunaga S, Kishi T, Yasue I, Iwata N (2015) Cholinesterase inhibitors for Lewy body disorders: a meta-analysis. Int J Neuropsychopharmacol 19(2).The meta-analysis included only randomized controlled trials and seventeen studies (n = 1798) were assessed. Cholinesterase inhibitors significantly improved cognitive function, behavioral disturbances, activities of daily living and global function compared with control treatments. Changes in motor function were not significantly different from control treatments. However treatment compliance and side effects needs to be monitored.","DOI":"10.1093\/ijnp\/pyv086"},{"issue":"2","key":"778_CR4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","volume":"86","author":"HF Wang","year":"2015","unstructured":"Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135\u201343.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"778_CR5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","volume":"172","author":"C Stinton","year":"2015","unstructured":"\u2022 Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(8):731\u201342. Forty-four studies examining 22 strategies were included in the review. Meta-analysis indicated beneficial effects of donepezil and rivastigmine for cognitive and psychiatric symptoms. Rivastigmine, but not donepezil, was associated with greater risk of adverse events. Meta-analysis of memantine suggested that it is well tolerated but with few benefits. Piracetam, amantadine, selegiline, olanzapine, quetiapine, risperidone, and citalopram do not appear to be effective.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"778_CR6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.23557","volume":"72","author":"E Mori","year":"2012","unstructured":"\u2022 Mori E, Ikeda M, Kosaka K, Donepezil DLBSI. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41\u201352. A randomized, double-blind, placebo-controlled exploratory phase 2 trial which recruited 140 patients with DLB, from 48 specialty centers in Japan, and given placebo or 3, 5, or 10 mg of donepezil hydrochloride daily for 12 weeks ( n\u00a0=\u00a035, 35, 33, and 37, respectively). Donepezil at 5 and 10mg\/day showed good tolerability and significant cognitive, behavioral, and global improvements that last at least 12 weeks in DLB patients, reducing caregiver burden at the highest dose.","journal-title":"Ann Neurol"},{"issue":"3\u20134","key":"778_CR7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000351672","volume":"36","author":"M Ikeda","year":"2013","unstructured":"\u2022 Ikeda M, Mori E, Kosaka K, Iseki E, Hashimoto M, Matsukawa N, et al. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord. 2013;36(3\u20134):229\u201341. A 52-week, multicenter, open-label extension study which administered donepezil at 5 mg\/day in patients with DLB and showed that it was well tolerated and had lasting effects on cognitive function and psychiatric symptoms up to 52 weeks.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"7","key":"778_CR8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","volume":"8","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613\u20138.","journal-title":"Lancet Neurol"},{"issue":"7","key":"778_CR9","doi-asserted-by":"crossref","first-page":"e005158","DOI":"10.1136\/bmjopen-2014-005158","volume":"4","author":"K Stubendorff","year":"2014","unstructured":"Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson\u2019s disease with dementia: a prospective study. BMJ Open. 2014;4(7):e005158.","journal-title":"BMJ Open"},{"issue":"5","key":"778_CR10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4088\/JCP.v66n0514","volume":"66","author":"D Aarsland","year":"2005","unstructured":"Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"778_CR11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","volume":"13","author":"DH Ffytche","year":"2017","unstructured":"Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017;13(2):81\u201395.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"778_CR12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.31887\/DCNS.2007.9.2\/dffytche","volume":"9","author":"DH Ffytche","year":"2007","unstructured":"Ffytche DH. Visual hallucinatory syndromes: past, present, and future. Dialogues Clin Neurosci. 2007;9(2):173\u201389.","journal-title":"Dialogues Clin Neurosci"},{"issue":"9916","key":"778_CR13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"\u2022\u2022 Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340. In this 6 week, randomised, double-blind, placebo-controlled study, 40 mg of Pimavanserin, a selective serotonin 5-HT2A inverse agonist was given to 95 patients with PDD and 90 patients received placebo. Pimavanserin improved psychosis and was well tolerated.","journal-title":"Lancet"},{"issue":"4","key":"778_CR14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology. 2010;35(4):881\u201392.","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"778_CR15","doi-asserted-by":"crossref","first-page":"898 e1","DOI":"10.1016\/j.jamda.2015.06.021","volume":"16","author":"C Ballard","year":"2015","unstructured":"Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J Am Med Dir Assoc. 2015;16(10):898 e1\u20137.","journal-title":"J Am Med Dir Assoc"},{"key":"778_CR16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.12659\/AJCR.900620","volume":"17","author":"Y Saito","year":"2016","unstructured":"Saito Y, Ishikawa J, Harada K. Postprandial and orthostatic hypotension treated by Sitagliptin in a patient with dementia with Lewy bodies. Am J Case Rep. 2016;17:887\u201393.","journal-title":"Am J Case Rep"},{"issue":"5\u20136","key":"778_CR17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000471507","volume":"43","author":"MI Lapid","year":"2017","unstructured":"\u2022 Lapid MI, Kuntz KM, Mason SS, Aakre JA, Lundt ES, Kremers W, et al. Efficacy, safety, and tolerability of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies: a pilot study. Dement Geriatr Cogn Disord. 2017;43(5\u20136):269\u201380. In this 12-week pilot trial of armodafinil therapy (125-250 mg orally daily) in DLB outpatients with hypersomnia, 17 patients out of 20 completed the protocol. Armodafanil therapy was found to be reasonably safe and tolerable and improved hypersomnia, wakefulness and also NPI scores and caregiver quality of life.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"7","key":"778_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17070","volume":"17","author":"S Banerjee","year":"2013","unstructured":"Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial\u2014a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess. 2013;17(7):1\u2013166.","journal-title":"Health Technol Assess"},{"issue":"Suppl 1","key":"778_CR19","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.parkreldis.2015.09.034","volume":"22","author":"D Aarsland","year":"2016","unstructured":"Aarsland D. Cognitive impairment in Parkinson\u2019s disease and dementia with Lewy bodies. Parkinsonism Relat Disord. 2016;22(Suppl 1):S144\u20138.","journal-title":"Parkinsonism Relat Disord"},{"issue":"23","key":"778_CR20","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1212\/WNL.0000000000001043","volume":"83","author":"J Pena","year":"2014","unstructured":"Pena J, Ibarretxe-Bilbao N, Garcia-Gorostiaga I, Gomez-Beldarrain MA, Diez-Cirarda M, Ojeda N. Improving functional disability and cognition in Parkinson disease: randomized controlled trial. Neurology. 2014;83(23):2167\u201374.","journal-title":"Neurology"},{"key":"778_CR21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2377-14-61","volume":"14","author":"C Strouwen","year":"2014","unstructured":"Strouwen C, Molenaar EA, Keus SH, Munks L, Munneke M, Vandenberghe W, et al. Protocol for a randomized comparison of integrated versus consecutive dual task practice in Parkinson\u2019s disease: the DUALITY trial. BMC Neurol. 2014;14:61.","journal-title":"BMC Neurol"},{"key":"778_CR22","unstructured":"\u2022 Strouwen C, Molenaar E, Munks L, Keus SHJ, Zijlmans JCM, Vandenberghe W, et al. Training dual tasks together or apart in Parkinson\u2019s disease: results from the DUALITY trial. Mov Disord 2017. In this randomized study patients ( N\u00a0=\u00a0121) with a diagnosis of PD were randomized to 6 weeks of at-home physiotherapist-led Training: (1) a consecutive group in which gait and cognitive tasks were trained separately or (2) an integrated group in which gait and cognitive tasks were trained simultaneously. Consecutive and integrated dual-task training showed similar and sustained improvements in dual-task gait velocity without increasing fall risk."},{"key":"778_CR23","doi-asserted-by":"crossref","unstructured":"\u2022 Diez-Cirarda M, Ojeda N, Pena J, Cabrera-Zubizarreta A, Lucas-Jimenez O, Gomez-Esteban JC, et al. Increased brain connectivity and activation after cognitive rehabilitation in Parkinson\u2019s disease: a randomized controlled trial. Brain Imaging Behav 2016. A randomized controlled trial three-month which used integrative cognitive rehabilitation program (REHACOP). Forty-four PD patients were randomly divided into REHACOP group (cognitive rehabilitation) and a control group (occupational therapy) and found that an integrative cognitive rehabilitation program can produce significant functional cerebral changes in PD patients and cognitive performance.","DOI":"10.1007\/s11682-016-9639-x"},{"issue":"4","key":"778_CR24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","volume":"13","author":"D Aarsland","year":"2017","unstructured":"Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217\u201331.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"778_CR25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12883-016-0731-z","volume":"16","author":"SC Weijer van de","year":"2016","unstructured":"van de Weijer SC, Duits AA, Bloem BR, Kessels RP, Jansen JF, Kohler S, et al. The Parkin'Play study: protocol of a phase II randomized controlled trial to assess the effects of a health game on cognition in Parkinson's disease. BMC Neurol. 2016;16(1):209.","journal-title":"BMC Neurol"},{"issue":"12","key":"778_CR26","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/mds.26291","volume":"30","author":"FJ David","year":"2015","unstructured":"\u2022 David FJ, Robichaud JA, Leurgans SE, Poon C, Kohrt WM, Goldman JG, et al. Exercise improves cognition in Parkinson\u2019s disease: the PRET-PD randomized, clinical trial. Mov Disord. 2015;30(12):1657\u201363. In this prospective, parallel-group, single-center randomized controlled trial, 51 nondemented patients with mild-to-moderate PD were randomly assigned either to modified Fitness Counts (mFC) or to Progressive Resistance Exercise Training (PRET) and were followed for 24 months. This study provides class IV level of evidence that 24 months of PRET or mFC may improve attention and working memory in nondemented patients with mild-to-moderate PD.","journal-title":"Mov Disord"},{"issue":"6","key":"778_CR27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neucli.2016.10.002","volume":"46","author":"JP Lefaucheur","year":"2016","unstructured":"Lefaucheur JP. A comprehensive database of published tDCS clinical trials (2005-2016). Neurophysiol Clin. 2016;46(6):319\u201398.","journal-title":"Neurophysiol Clin"},{"issue":"2","key":"778_CR28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1017\/S1041610215001180","volume":"28","author":"GJ Elder","year":"2016","unstructured":"\u2022 Elder GJ, Firbank MJ, Kumar H, Chatterjee P, Chakraborty T, Dutt A, et al. Effects of transcranial direct current stimulation upon attention and visuoperceptual function in Lewy body dementia: a preliminary study. Int Psychogeriatr. 2016;28(2):341\u20137. Attentional, but not visuoperceptual, improved following tDCS in 13 patients with LBD. Larger-scale, placebo-controlled trials are suggested to confirm whether tDCS is a useful treatment option for attentional deficits in LBD.","journal-title":"Int Psychogeriatr"},{"key":"778_CR29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cortex.2016.11.016","volume":"88","author":"E Heinrichs-Graham","year":"2017","unstructured":"Heinrichs-Graham E, McDermott TJ, Mills MS, Coolidge NM, Wilson TW. Transcranial direct-current stimulation modulates offline visual oscillatory activity: a magnetoencephalography study. Cortex. 2017;88:19\u201331.","journal-title":"Cortex"},{"issue":"2","key":"778_CR30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1479-8301.2009.00292.x","volume":"9","author":"S Takahashi","year":"2009","unstructured":"Takahashi S, Mizukami K, Yasuno F, Asada T. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics. 2009;9(2):56\u201361.","journal-title":"Psychogeriatrics"},{"issue":"Suppl 12","key":"778_CR31","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1002\/mds.20538","volume":"20","author":"GK Tofaris","year":"2005","unstructured":"Tofaris GK, Spillantini MG. Alpha-synuclein dysfunction in Lewy body diseases. Mov Disord. 2005;20(Suppl 12):S37\u201344.","journal-title":"Mov Disord"},{"issue":"12","key":"778_CR32","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65(12):1863\u201372.","journal-title":"Neurology"},{"issue":"8","key":"778_CR33","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","volume":"8","author":"L Maroteaux","year":"1988","unstructured":"Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8(8):2804\u201315.","journal-title":"J Neurosci"},{"issue":"24","key":"778_CR34","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1523\/JNEUROSCI.1091-10.2010","volume":"30","author":"DA Scott","year":"2010","unstructured":"Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci. 2010;30(24):8083\u201395.","journal-title":"J Neurosci"},{"issue":"1","key":"778_CR35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.25373","volume":"28","author":"CW Olanow","year":"2013","unstructured":"Olanow CW, Brundin P. Parkinson\u2019s disease and alpha synuclein: is Parkinson\u2019s disease a prion-like disorder? Mov Disord. 2013;28(1):31\u201340.","journal-title":"Mov Disord"},{"issue":"4","key":"778_CR36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.bcp.2014.01.015","volume":"88","author":"CR Overk","year":"2014","unstructured":"Overk CR, Masliah E. Pathogenesis of synaptic degeneration in Alzheimer\u2019s disease and Lewy body disease. Biochem Pharmacol. 2014;88(4):508\u201316.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"778_CR37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/jnnp-2016-314832","volume":"88","author":"DH Ffytche","year":"2017","unstructured":"Ffytche DH, Pereira JB, Ballard C, Chaudhuri KR, Weintraub D, Aarsland D. Risk factors for early psychosis in PD: insights from the Parkinson\u2019s progression markers initiative. J Neurol Neurosurg Psychiatry. 2017;88(4):325\u201331.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"778_CR38","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1353-8020(11)70006-2","volume":"18","author":"A Schneeberger","year":"2012","unstructured":"Schneeberger A, Mandler M, Mattner F, Schmidt W. Vaccination for Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S11\u20133.","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"778_CR39","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","volume":"127","author":"M Mandler","year":"2014","unstructured":"\u2022\u2022 Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson\u2019s disease clinical trials. Acta Neuropathol. 2014;127(6):861\u201379. This study investigated the potential therapeutical value of active vaccination with novel \u03b1-syn AFFITOPEs\u00ae (AFF) in two different tg models of PD and DLB-like pathology and based on these results, a Phase I clinical trial for PD has been initiated.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"778_CR40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/imt.13.162","volume":"6","author":"V Lindstrom","year":"2014","unstructured":"Lindstrom V, Ihse E, Fagerqvist T, Bergstrom J, Nordstrom E, Moller C, et al. Immunotherapy targeting alpha-synuclein, with relevance for future treatment of Parkinson\u2019s disease and other Lewy body disorders. Immunotherapy. 2014;6(2):141\u201353.","journal-title":"Immunotherapy"},{"issue":"2","key":"778_CR41","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ana.22319","volume":"69","author":"E Himeno","year":"2011","unstructured":"Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, et al. Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. Ann Neurol. 2011;69(2):248\u201356.","journal-title":"Ann Neurol"},{"issue":"5","key":"778_CR42","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.26422","volume":"31","author":"AJ Yarnall","year":"2016","unstructured":"Yarnall AJ, Lashley T, Ling H, Lees AJ, Coleman SY, O'Sullivan SS, et al. Apomorphine: a potential modifier of amyloid deposition in Parkinson\u2019s disease? Mov Disord. 2016;31(5):668\u201375.","journal-title":"Mov Disord"},{"issue":"4","key":"778_CR43","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"\u2022 Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov Disord. 2015;30(4):510\u20136. This open-label, prospective, observational, 6-month, multicenter study compared 43 PD patients on subcutaneous apomorphine infusion and 44 on intrajejunal levodopa infusion and found improvement in motor symptoms, nonmotor symptoms, quality-of-life and some NMS.","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"778_CR44","first-page":"131","volume":"9","author":"E Rockenstein","year":"2015","unstructured":"Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A, et al. Neuropeptide treatment with cerebrolysin enhances the survival of grafted neural stem cell in an alpha-synuclein transgenic model of Parkinson\u2019s disease. J Exp Neurosci. 2015;9(Suppl 2):131\u201340.","journal-title":"J Exp Neurosci"},{"issue":"Pt 9","key":"778_CR45","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/brain\/awm167","volume":"130","author":"V Bogaerts","year":"2007","unstructured":"Bogaerts V, Engelborghs S, Kumar-Singh S, Goossens D, Pickut B, van der Zee J, et al. A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain. 2007;130(Pt 9):2277\u201391.","journal-title":"Brain"},{"issue":"19","key":"778_CR46","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/WNL.0b013e3182735e9a","volume":"79","author":"D Tsuang","year":"2012","unstructured":"Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology. 2012;79(19):1944\u201350.","journal-title":"Neurology"},{"issue":"6","key":"778_CR47","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4161\/mabs.21696","volume":"4","author":"SN Joshi","year":"2012","unstructured":"Joshi SN, Butler DC, Messer A. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. MAbs. 2012;4(6):686\u201393.","journal-title":"MAbs"},{"issue":"1","key":"778_CR48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","volume":"13","author":"E Valera","year":"2016","unstructured":"\u2022 Valera E, Spencer B, Masliah E. Immunotherapeutic approaches targeting amyloid-beta, alpha-synuclein, and tau for the treatment of neurodegenerative disorders. Neurotherapeutics. 2016;13(1):179\u201389. This paper provides an overview of the most novel and relevant immunotherapeutic advances as promising therapeutic approach for neurodegenerative diseases that progress with the accumulation and prion-like propagation of toxic protein aggregates.","journal-title":"Neurotherapeutics"},{"key":"778_CR49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","volume":"145-146","author":"D Athauda","year":"2016","unstructured":"\u2022 Athauda D, Foltynie T. Insulin resistance and Parkinson\u2019s disease: a new target for disease modification. Prog Neurobiol. 2016;145-146:98\u2013120. A review of the underlying cellular links between insulin resistance and the pathogenesis of PD and which discusses current and future pharmacological strategies being developed to restore neuronal insulin signalling as a potential strategy for slowing neurodegeneration in Parkinson's disease.","journal-title":"Prog Neurobiol"},{"issue":"4","key":"778_CR50","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316\u201338.","journal-title":"J Clin Invest"},{"key":"778_CR51","first-page":"353","volume":"5","author":"LE Stoeckel","year":"2016","unstructured":"Stoeckel LE, Arvanitakis Z, Gandy S, Small D, Kahn CR, Pascual-Leone A, et al. Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction. F1000Res. 2016;5:353.","journal-title":"F1000Res"},{"issue":"2","key":"778_CR52","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jcb.22272","volume":"108","author":"JF Tong","year":"2009","unstructured":"Tong JF, Yan X, Zhu MJ, Du M. AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1\/Akt signaling in C2C12 myotubes. J Cell Biochem. 2009;108(2):458\u201368.","journal-title":"J Cell Biochem"},{"issue":"2","key":"778_CR53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/mds.26428","volume":"31","author":"E Valera","year":"2016","unstructured":"Valera E, Masliah E. Combination therapies: the next logical step for the treatment of synucleinopathies? Mov Disord. 2016;31(2):225\u201334.","journal-title":"Mov Disord"},{"issue":"12","key":"778_CR54","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.neurobiolaging.2014.06.015","volume":"35","author":"DR Whitfield","year":"2014","unstructured":"Whitfield DR, Vallortigara J, Alghamdi A, Howlett D, Hortobagyi T, Johnson M, et al. Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. Neurobiol Aging. 2014;35(12):2836\u201344.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"778_CR55","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1073\/pnas.1220464110","volume":"110","author":"SP Sardi","year":"2013","unstructured":"Sardi SP, Clarke J, Viel C, Chan M, Tamsett TJ, Treleaven CM, et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci U S A. 2013;110(9):3537\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"778_CR56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13041-016-0264-9","volume":"9","author":"H Xing","year":"2016","unstructured":"Xing H, Lim YA, Chong JR, Lee JH, Aarsland D, Ballard CG, et al. Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with beta-amyloid burden and synaptic deficits in Lewy body dementias. Mol Brain. 2016;9(1):84.","journal-title":"Mol Brain"},{"issue":"1","key":"778_CR57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JAD-160781","volume":"56","author":"JR Chong","year":"2017","unstructured":"Chong JR, Chai YL, Lee JH, Howlett D, Attems J, Ballard CG, et al. Increased transforming growth factor beta2 in the neocortex of Alzheimer\u2019s disease and dementia with Lewy bodies is correlated with disease severity and soluble Abeta42 load. J Alzheimer's Dis. 2017;56(1):157\u201366.","journal-title":"J Alzheimer's Dis"},{"issue":"4","key":"778_CR58","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/nan.12260","volume":"42","author":"JH Baek","year":"2016","unstructured":"Baek JH, Whitfield D, Howlett D, Francis P, Bereczki E, Ballard C, et al. Unfolded protein response is activated in Lewy body dementias. Neuropathol Appl Neurobiol. 2016;42(4):352\u201365.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"778_CR59","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2174\/1567205011310060002","volume":"10","author":"KM Al-Mansoori","year":"2013","unstructured":"Al-Mansoori KM, Hasan MY, Al-Hayani A, El-Agnaf OM. The role of alpha-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches. Curr Alzheimer Res. 2013;10(6):559\u201368.","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"778_CR60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1756285613493469","volume":"7","author":"DR Jones","year":"2014","unstructured":"Jones DR, Moussaud S, McLean P. Targeting heat shock proteins to modulate alpha-synuclein toxicity. Ther Adv Neurol Disord. 2014;7(1):33\u201351.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"778_CR61","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nn.3637","volume":"17","author":"X Fan","year":"2014","unstructured":"Fan X, Jin WY, Lu J, Wang J, Wang YT. Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci. 2014;17(3):471\u201380.","journal-title":"Nat Neurosci"},{"issue":"2","key":"778_CR62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrneurol.2013.275","volume":"10","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Bae EJ, Lee SJ. Extracellular alpha\u2014synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol. 2014;10(2):92\u20138.","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"778_CR63","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jamda.2008.07.001","volume":"9","author":"W Tse","year":"2008","unstructured":"Tse W, Frisina PG, Halbig TD, Gracies JM, Liang L, Tarshish C, et al. The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism. J Am Med Dir Assoc. 2008;9(9):670\u20135.","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"778_CR64","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/0891988707303335","volume":"20","author":"HB Lee","year":"2007","unstructured":"Lee HB, Hanner JA, Yokley JL, Appleby B, Hurowitz L, Lyketsos CG. Clozapine for treatment-resistant agitation in dementia. J Geriatr Psychiatry Neurol. 2007;20(3):178\u201382.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"5","key":"778_CR65","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"778_CR66","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.sleep.2012.09.018","volume":"14","author":"SJ McCarter","year":"2013","unstructured":"McCarter SJ, Boswell CL, St Louis EK, Dueffert LG, Slocumb N, Boeve BF, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013;14(3):237\u201342.","journal-title":"Sleep Med"},{"issue":"2","key":"778_CR67","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/psyg.12043","volume":"14","author":"H Fujishiro","year":"2014","unstructured":"Fujishiro H. Effects of gabapentin enacarbil on restless legs syndrome and leg pain in dementia with Lewy bodies. Psychogeriatrics. 2014;14(2):132\u20134.","journal-title":"Psychogeriatrics"},{"issue":"5","key":"778_CR68","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.stemcr.2015.09.008","volume":"5","author":"NR Goldberg","year":"2015","unstructured":"Goldberg NR, Caesar J, Park A, Sedgh S, Finogenov G, Masliah E, et al. Neural stem cells rescue cognitive and motor dysfunction in a transgenic model of dementia with Lewy bodies through a BDNF-dependent mechanism. Stem Cell Rep. 2015;5(5):791\u2013804.","journal-title":"Stem Cell Rep"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-017-0778-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-017-0778-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-017-0778-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T10:44:45Z","timestamp":1659264285000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-017-0778-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s11910-017-0778-2","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]},"article-number":"68"}}